fashion -WSS

fashion

author：focus 2025-09-03 03:27:06 - browse：94639

KalVista Pharmaceuticals said Tuesday that its oral, on-demand treatment for the swelling “attacks” commonly experienced by patients with a genetic condition called hereditary angioedema achieved the goals of a Phase 3 clinical trial.

Based on the study results, the company plans to submit a marketing application to the Food and Drug Administration by the middle of the year. Regulatory filings in Europe and Japan will be completed later in the year.

In the Phase 3 study involving 136 participants, a low and high dose of Kalvista’s drug, called sebetralstat, showed a median time to the beginning of symptom relief of 1.6 hours and 1.8 hours, respectively, compared to 6.7 hours for a placebo. The result was statistically significant and achieved the study’s main efficacy goal.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： U.K. officials, researchers try to ease path for bespoke genetic treatments

explore

WSS

Spinal cord stimulation reduces pain in amputees, study finds

Yancopoulos of Regeneron works to expand Dupixent success

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

Spinal cord stimulation reduces pain in amputees, study finds

SCOTUS to consider access to abortion pill mifepristone

CRISPR technology availability, affordability needs to be expanded

hotspot

fashion

entertainment

Bright Health sells Medicare Advantage business to Molina

Testing GLP

The high cost of giving birth even with insurance

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

Guidelines to prevent youth baseball injuries need more muscle

Diabetes management: Digital health tools fall short, study says

Medical leaders decry Supreme Court decision on affirmative action

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

FDA approves world's first CRISPR

hotspot

What PEPFAR has meant on the ground in Ukraine

FDA approves world's first CRISPR

Why sickle cell disease is getting the first CRISPR treatment

U.K. officials, researchers try to ease path for bespoke genetic treatments

Pregnancy discrimination could be enabled by AI

Surgeons perform first xenotransplant using CRISPR'd pig kidney

explore

knowledge

hotspot

leisure time